409 related articles for article (PubMed ID: 26748222)
21. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.
Singh S; Manickam P; Amin AV; Samala N; Schouten LJ; Iyer PG; Desai TK
Gastrointest Endosc; 2014 Jun; 79(6):897-909.e4; quiz 983.e1, 983.e3. PubMed ID: 24556051
[TBL] [Abstract][Full Text] [Related]
22. Risk of progression of Barrett's esophagus in patients with cirrhosis.
Apfel T; Lopez R; Sanaka MR; Thota PN
World J Gastroenterol; 2017 May; 23(18):3287-3294. PubMed ID: 28566888
[TBL] [Abstract][Full Text] [Related]
23. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
[TBL] [Abstract][Full Text] [Related]
24. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
25. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
26. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
[TBL] [Abstract][Full Text] [Related]
28. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
29. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
30. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
[TBL] [Abstract][Full Text] [Related]
31. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Barrie J; Yanni F; Sherif M; Dube AK; Tamhankar AP
Surg Endosc; 2021 Aug; 35(8):4756-4762. PubMed ID: 32880012
[TBL] [Abstract][Full Text] [Related]
32. Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.
Small AJ; Araujo JL; Leggett CL; Mendelson AH; Agarwalla A; Abrams JA; Lightdale CJ; Wang TC; Iyer PG; Wang KK; Rustgi AK; Ginsberg GG; Forde KA; Gimotty PA; Lewis JD; Falk GW; Bewtra M
Gastroenterology; 2015 Sep; 149(3):567-76.e3; quiz e13-4. PubMed ID: 25917785
[TBL] [Abstract][Full Text] [Related]
33. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
34. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
[TBL] [Abstract][Full Text] [Related]
35. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
[TBL] [Abstract][Full Text] [Related]
36. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
Bowman CJ; Zhang R; Balitzer D; Wang D; Rabinovitch PS; Kővári BP; Mattis AN; Kakar S; Lauwers GY; Choi WT
Mod Pathol; 2021 Oct; 34(10):1889-1900. PubMed ID: 34108638
[TBL] [Abstract][Full Text] [Related]
37. Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
Tsoi EH; Mahindra P; Cameron G; Williams R; Norris R; Desmond PV; Raftopoulos S; Pavey D; Rattan A; Hourigan LF; Lee R; Bourke MJ; Sidhu N; Singh R; Chan A; Krishnamurthi S; Taylor ACF
Gastrointest Endosc; 2021 Nov; 94(5):902-908. PubMed ID: 34033852
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
Wang Y; Ma B; Yang S; Li W; Li P
Front Oncol; 2022; 12():801940. PubMed ID: 35296005
[TBL] [Abstract][Full Text] [Related]
39. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
[TBL] [Abstract][Full Text] [Related]
40. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review.
Wani S; Puli SR; Shaheen NJ; Westhoff B; Slehria S; Bansal A; Rastogi A; Sayana H; Sharma P
Am J Gastroenterol; 2009 Feb; 104(2):502-13. PubMed ID: 19174812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
